Kineret — CareFirst (Caremark)
Adult-onset Still’s disease (AOSD)
Reauthorization criteria
- Member achieves or maintains a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms, demonstrated by improvement in any of the following from baseline: number of joints with active arthritis, number of joints with limitation of movement, functional ability, or systemic features (fever, evanescent rash, lymphadenopathy, hepatomegaly, splenomegaly, serositis).
Approval duration
12 months